ILIAS Biologics Secured Phase 1 Results for Exosome Therapeutic and Published Research Results in International Journal
Expected to demonstrate higher safety compared to existing anti-inflammatory treatments, signaling a strong entry into the global market EUNPYEONG-GU, SEOUL, KOREA, July 23, 2024 /EINPresswire.com/ -- ILIAS Biologics Inc. (CEO Chulhee Choi, hereinafter …